Seasonal Influenza Vaccine Use by Adults in the U.S.

Detailed Survey Tables, Mid-November 2009

Katherine M. Harris, Jürgen Maurer, Lori Uscher-Pines

ResearchPublished Dec 7, 2009

In mid-November 2009, RAND conducted a survey of a nationally representative sample of adults age 18 and over (n=5,679) to collect data on the uptake of the seasonal influenza vaccine in the United States. The detailed survey data presented here will inform public health officials and other stakeholders about progress toward vaccinating adults prior to the end of the vaccination season in late winter while action can still be taken to improve vaccination rates for this flu season. In particular, it provides information on vaccination uptake for adults specifically recommended for the vaccine by the Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention (CDC), including those age 50 or over; persons having certain high-risk medical conditions; health care workers; women who will be pregnant during flu season; residents of nursing homes or other long-term care facilities; and those having close contact with or caring for children under 5 years of age, persons age 50 or over, or other high-risk individuals.

Topics

Document Details

  • Copyright: RAND Corporation
  • Availability: Web-Only
  • Year: 2009
  • Pages: 3
  • Document Number: OP-289/1-GSK

Citation

RAND Style Manual
Harris, Katherine M., Jürgen Maurer, and Lori Uscher-Pines, Seasonal Influenza Vaccine Use by Adults in the U.S. Detailed Survey Tables, Mid-November 2009, RAND Corporation, OP-289/1-GSK, 2009. As of October 3, 2024: https://www.rand.org/pubs/occasional_papers/OP289z1.html
Chicago Manual of Style
Harris, Katherine M., Jürgen Maurer, and Lori Uscher-Pines, Seasonal Influenza Vaccine Use by Adults in the U.S. Detailed Survey Tables, Mid-November 2009. Santa Monica, CA: RAND Corporation, 2009. https://www.rand.org/pubs/occasional_papers/OP289z1.html.
BibTeX RIS

This survey was conducted with the funding and support of GlaxoSmithKline (GSK). The research described in this report was performed under the auspices of RAND Health.

This publication is part of the RAND occasional paper series. RAND occasional papers were products of RAND from 2003 to 2013 that included informed perspectives on a timely policy issue, discussions of new research methodologies, essays, papers presented at a conference, and summaries of work in progress.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.